Algernon Pharmaceuticals: Developing Drugs for Global Diseases

Fast-tracking drugs into human trials

Algernon Pharmaceuticals is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) and chronic cough, and COVID-19.

The company and its business model are highly capital efficient and strive to deliver maximum shareholder value. Algernon’s unique approach to drug discovery is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several potential benefits over traditional drug development including a reduction in investment and risk, shorter research periods, and a longer active patent life.

The company enters into a clinical trial agreement with Yale University for a DMT phase 2 depression study.

For more information on Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) please click the request investor info button.